Travis Whitfill
About Travis Whitfill
Travis Whitfill is Azitra’s co-founder, Chief Operating Officer (since June 2023), and a director serving on the Board since inception. He previously served as Chief Scientific Officer (Jan 2014–Sep 2019) and Director of Advanced Technology (since Sep 2019). He earned a B.S. from Dallas Baptist University, an MPH from Yale University, and a PhD from University College London, has led multiple grant-funded projects, holds several patents, and co-authored 70+ publications. Age 35 as of the 2025 proxy; no company TSR, revenue or EBITDA growth metrics are disclosed for his tenure in the proxy materials .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Azitra, Inc. | Chief Scientific Officer | 2014–2019 | Built scientific foundation; advanced live biotherapeutic programs |
| Azitra, Inc. | Director of Advanced Technology | 2019–present | Led technology strategy and innovation |
| Azitra, Inc. | Chief Operating Officer | Jun 2023–present | Operational leadership through clinical and financing milestones |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Bios Equity Partners, LP | Partner | 2015–2023 | VC investing; biotech portfolio support |
| Bios Research | Senior Analyst | 2014–2023 | Equity research in life sciences |
| Yale University | Associate Research Scientist; Assistant Professor Adjunct | 2016–2022; 2022–present | Academic research in Pediatrics and Emergency Medicine |
| IN8Bio, Inc. (Nasdaq: INAB) | Director | 2018–May 2025 | Public company governance in oncology |
| 410 Medical | Director | 2017–2019 | Medtech oversight |
| SIRPant Immunotherapeutics | Director | 2021–2023 | Immunotherapy venture governance |
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base Salary ($) | $158,846 | $380,000 |
| Target Bonus (%) | Up to 30% of base salary | Up to 30% of base salary |
| Actual Bonus Paid ($) | $0 | $88,350 |
| Option Awards ($, grant-date fair value) | $20,700 | $0 |
| All Other Compensation ($) | $2,767 | $4,460 |
| Total ($) | $182,313 | $472,810 |
| Employment Agreement Terms | Detail |
|---|---|
| Agreement date | July 5, 2023 |
| Role | Chief Operating Officer |
| Base Salary | $350,000 |
| Target Bonus | Up to 30% of base salary; based on Board-set performance parameters |
| Benefits | Health insurance and other executive benefits at company expense |
| Employment Status | At-will; either party may terminate with notice |
Performance Compensation
| Metric Category | Weighting | Target | Actual | Payout ($) | Vesting/Timing |
|---|---|---|---|---|---|
| Company-wide metrics: pre-clinical, clinical & regulatory, financial, investor relations | Not disclosed | Up to 30% of base salary | Company achieved 75% of metrics; individual payouts adjusted by goal attainment and job-level weighted score | 88,350 (FY2024) | Cash bonus for FY2024; paid per Compensation Committee approval |
Notes: The proxy discloses qualitative performance categories and that FY2024 bonuses were calibrated to 75% achievement with role-based weighting; specific metric weights and targets are not disclosed .
Option Awards — Grant Detail and Vesting
| Grant Date | Instrument | Shares | Strike ($) | Vesting | Expiration |
|---|---|---|---|---|---|
| Sep 8, 2023 | Stock Options | 333 | 62.10 | 25% cliff at 1st anniversary (83 sh); remaining 75% monthly over 36 months post-anniversary (250 sh) | Sep 8, 2033 |
Equity Ownership & Alignment
| Ownership Metric | Value |
|---|---|
| Total beneficial ownership (common shares) | 14,394 shares (<1% of 17,226,354 outstanding as of May 28, 2025) |
| Options — exercisable | 1,859 @ $14.32 expiring Jan 1, 2026; 1,246 @ $51.08 expiring Dec 16, 2030; 111 @ $62.10 expiring Sep 8, 2033 |
| Options — unexercisable | 222 @ $62.10 expiring Sep 8, 2033 (continues to vest ratably monthly) |
| RSUs/PSUs | None disclosed for Whitfill |
| Hedging/Pledging | Company Insider Trading Policy prohibits short sales, publicly traded options, hedging transactions, margin accounts, and pledged securities for directors/officers/employees |
| Stock Ownership Guidelines | Not disclosed in proxy materials |
| Trading Windows | Insider Trading Policy applies; preclearance and window practices implied via policy and SEC compliance |
Employment Terms
| Term | Whitfill (COO) |
|---|---|
| Severance on qualified involuntary termination (without cause/incapacity) | Continuation of base salary for 6 months; plus prior-year annual bonus if unpaid |
| Illustrative cash severance (had termination occurred 12/31/2024) | $278,350 (includes $190,000 salary and $88,350 bonus) |
| Change-in-control treatment | Cash severance available before/after change in control; no equity acceleration shown for Whitfill at 12/31/2024 |
| IP/Confidentiality/Indemnification | Customary provisions in agreement |
| Non-compete/Non-solicit/Garden leave | Not disclosed in proxy materials |
Board Governance (Director Service)
- Board service: Director since inception; not independent due to executive officer status .
- Board composition: Four directors; two independent (Barbara Ryan, John Schroer) per NYSE American rules for smaller reporting companies (50% independence threshold met) .
- Committees and roles: Audit Committee (Ryan, Schroer; Schroer chair); Compensation Committee (Ryan chair, Schroer); Nominating & Corporate Governance Committee (Ryan chair, Schroer). Committees consist solely of independent directors; Whitfill does not serve on committees .
- Attendance: In 2024, Board held four meetings; all directors attended at least 75% of Board and committee meetings. Schroer and Ryan attended the 2024 annual meeting; others did not; no policy requiring annual meeting attendance .
- Board leadership: No formal policy to separate chairperson and CEO; no lead independent director. Risk oversight delegated across committees, reporting to full Board .
- Director compensation policy: Executive directors are not compensated for Board service. Non-executive directors receive cash retainers (Board: $25,000; Committee chairs: $5,000 for Compensation and Nominating, $7,500 for Audit; Committee members: $3,500) and previously received 333-option grants in Sep 2023 with $62.10 strike and standard vesting .
Related Party Transactions, Clawbacks, Policies
- Related party transactions: None exceeding SEC thresholds since Jan 1, 2023, other than compensation arrangements described in the proxy .
- Clawback/Recoupment policy: Not disclosed in proxies reviewed; Insider Trading Policy attached to 2024 10-K, with prohibitions on hedging/pledging and specified speculative transactions .
- Indemnification: Company provides indemnification to officers/directors per charter/bylaws and written agreements; standard DGCL limitations of liability apply .
Risk Indicators & Red Flags
- Dilution risk: Equity line with Alumni Capital LP up to $20 million through Dec 31, 2026; already sold 2,247,000 shares by May 28, 2025. Could increase volatility and impact insider alignment via dilution of ownership stakes .
- Option overhang and expirations: Multiple options are in-the-money/out-of-the-money with staggered expirations, including a near-term 2026 expiry at $14.32, potentially influencing exercise/sale decisions when trading windows open .
- Governance dual-role: Executive-director status reduces board independence; however, committees are fully independent and chaired by non-executives, which mitigates some concerns .
- Clawback transparency: Lack of disclosed clawback policy reduces pay-for-performance enforcement clarity relative to evolving listing standards .
Investment Implications
- Pay-for-performance linkage: Whitfill’s bonus structure is explicitly tied to company-wide operational/financial/IR metrics with role-based weighting; FY2024 payout of $88,350 against a 30% target indicates moderate alignment, contingent on milestone execution .
- Retention risk: Severance equals six months of salary plus prior-year bonus (if unpaid) and no equity acceleration shown for Whitfill; retention rests on ongoing equity vesting schedules and operational milestones rather than rich change-in-control benefits, lowering “golden parachute” risk .
- Trading signals: Prohibition on hedging/pledging reduces adverse alignment behaviors; absence of Form 4 activity located suggests limited recent insider selling signals for Whitfill, while the monthly vesting of 2023 options and 2026/2030/2033 expirations create predictable windows for potential exercises/sales that traders should monitor around earnings and news cycles .
- Governance quality: Dual executive-director role is counterbalanced by independent committee structures and active oversight, but the absence of a lead independent director and no disclosed clawback policy are governance watch points for investors .
Appendix: Outstanding Equity Awards (as of Dec 31, 2024)
| Name | Exercisable Options (#) | Unexercisable Options (#) | Strike ($) | Expiration |
|---|---|---|---|---|
| Travis Whitfill | 1,859 | 0 | 14.32 | 01/01/2026 |
| Travis Whitfill | 1,246 | 0 | 51.08 | 12/16/2030 |
| Travis Whitfill | 111 | 222 | 62.10 | 09/08/2033 |
Appendix: Beneficial Ownership (as of May 28, 2025)
| Holder | Shares Beneficially Owned | % of Outstanding |
|---|---|---|
| Travis Whitfill | 14,394 | <1% (of 17,226,354 shares outstanding) |
Sources
- DEF 14A (May 29, 2025): Biography, compensation tables, employment agreements, committees, beneficial ownership, policies .
- DEF 14A (Oct 9, 2024): Prior compensation details, equity awards, termination payments, employment agreements .